research Refractory dermatomyositis–systemic lupus erythematosus overlap syndrome and response to tofacitinib
Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
Search
for
Sort by
Research
270-300 / 1000+ results
research Trazodone and chlorpromazine a proposal treatment for syndrome post-finasteride and syndrome of post-selective serotonin reuptake inhibitors (post-SSRI)
Trazodone and chlorpromazine may help treat sexual dysfunction caused by finasteride and SSRIs.
research Marie Antoinette syndrome following COVID‐19 vaccination
A woman experienced sudden hair graying and loss after a COVID-19 vaccine, which improved with treatment.
research 33813 Retrospective study of the prevalence of hyperkalemia in women taking spironolactone for acne, hair loss, and hirsutism
Monitoring potassium levels is important for women taking spironolactone.
research Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
research MON-323 Metastatic Adrenocortical Carcinoma Presenting with Mixed Cushing's and Virilization Syndrome along with Bilateral Pulmonary Emboli
Rapid virilization should be checked for possible ovarian or adrenal cancer.
research Severe and refractory hypotension after intentional minoxidil overdose: a case report
Minoxidil overdose caused severe low blood pressure, but the patient recovered with specific treatments.
research Tourniquet syndrome in children (literature review and own observation)
Quick action and prevention are crucial to avoid severe complications from tourniquet syndrome in children.
research The Double-Edged Sword of Epidermal Growth Factor Receptor Inhibitor: Rash as Toxicity and Prognostic Marker
A 50-year-old man undergoing treatment with the epidermal growth factor receptor inhibitor (EGFRI) lapatinib for stage 2 breast carcinoma developed a papulopustular rash, a common side effect of EGFRIs, affecting 50-100% of patients. This rash, part of the 'PRIDE' complex, includes various cutaneous adverse effects such as xerosis and eczema. The patient was treated with doxycycline and hydrocortisone cream, showing significant improvement within a week. Acneiform eruptions, which lack comedones, may serve as a potential marker for therapeutic response to EGFRI drugs, although evidence is inconsistent. The rash typically appears within 1-2 weeks of therapy, peaks at 3-4 weeks, and subsides gradually. Patients are advised on sun protection and gentle skincare to manage symptoms.
research MON-407 The Double-Edged Sword of Methimazole: Managing Graves' Disease with a Twist
Methimazole can cause severe low platelet count in Graves' disease patients, so monitoring and alternative treatments are important.
research SAT-369 Marine-Lenhart Syndrome: Case Report
Combining medication and minimally invasive techniques can effectively manage Marine-Lenhart syndrome.
research Drug eruptions in dermatology
Skin reactions to drugs are common and can be deadly, usually requiring stopping the drug and may be better prevented with genetic testing in the future.
research Encephalitis lethargica due to Epstein–Barr virus infection
Finasteride may help reduce tic severity in male Tourette syndrome patients.
research Sodium Valproate-Induced Hyperpigmentation
Sodium valproate can rarely cause skin darkening, which may improve after stopping the drug.
research Correlation between Traditional Chinese Medicine Syndromes and Type 2 Myocardial Infarction in Critically Ill Patients with Pulmonary Disease
Patients with deficiency syndrome, especially qi deficiency, have a higher risk of type 2 heart attacks.
research 증례 : 몸통의 다발성 판으로 나타난 Bortezomib에 의한 약물 발진 2예
Bortezomib chemotherapy can cause temporary skin rashes.
research Hoffman syndrome with the classic sign of myoedema and an unusual finding of systolic heart failure
Thyroid hormone therapy effectively treated the man's rare muscle and heart issues.
research The Rare Occurrence of a Left Atrial Thrombus in a Dog
A dog with a rare heart clot died despite treatment, highlighting the need for better clot treatments in dogs.
research Side Effects and Adverse Events After Treatment With Teprotumumab for Thyroid Eye Disease: A Retrospective Observational Case Series
Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.
research The Post-Finasteride Syndrome After Distinct Doses/Affections
research Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
research Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats
research PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators
PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.
research Management of the adverse effects of targeted therapy for cancer
Targeted cancer therapies can cause new side effects, requiring careful monitoring and management to ensure patient safety.
research Risk of valproic acid-related alopecia: A systematic review and meta-analysis
Valproic acid increases the risk of hair loss more than other drugs, especially in migraine patients, and lamotrigine may be a safer alternative.
research Sodium valproate and thrombocytopenia.
Sodium valproate can cause low platelet count.
research 33813 Retrospective study of the prevalence of hyperkalemia in women taking spironolactone for acne, hair loss, and hirsutism
Dermatologists should monitor potassium levels in women taking spironolactone for acne, hair loss, and hirsutism.
research Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
research An urticarial drug eruption caused by tofacitinib for alopecia universalis
A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.